Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19

Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19

BACKGROUND Severe cases of coronavirus disease 2019 (COVID-19) are characterized by progressive respiratory failure and the development of acute respiratory distress syndrome (ARDS), with high mortality rates for patients requiring mechanical ventilation. Levels of the vascular growth factor Angiopo...

Full description

Bibliographic Details
Main Authors: Rosie S. Jones, Patricia S. Smith, Paul H. Berg, Amparo de la Peña, Paul P. Cook, Imad Shawa, Kathleen M. Kioussopoulos, Yu Hu, Robert J. Schott
Format: Article
Language:English
Published: SAGE Publishing 2022-08-01
Series:Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
Online Access:https://doi.org/10.1177/11795484221119316

Internet

https://doi.org/10.1177/11795484221119316

Similar Items